Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoraci...

  • Satoshi Ikeda, Terufumi Kato, Takashi Ogura, Akimasa Sekine, Tsuneyuki Oda, Noriyuki Masuda, Satoshi Igawa, Ken Katono, Sakiko Otani, Kouzo Yamada, Haruhiro Saito, Tetsuro Kondo, Yukio Hosomi, Yoshiro Nakahara, Masanori Nishikawa, Keiko Utumi, Yuki Misumi, Takeharu Yamanaka, Kentaro Sakamaki, Hiroaki Okamoto
  • BMC Cancer, March 2018, Springer Science + Business Media
  • DOI: 10.1186/s12885-018-4150-y

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1186/s12885-018-4150-y

The following have contributed to this page: Satoshi Ikeda